(BAN, USAN, rINN)
Synonyms: CDDP; Cisplatina; Cisplatine; Cisplatino; Cisplatinum; Cis-platinum; Ciszplatin; DDP; cis-DDP; NSC-119875; Peyrone’s Salt; Platinum Diamminodichloride; Sisplatiini; Sisplatin. cis-Diamminedichloroplatinum.
Cyrillic synonym: Цисплатин.
Chemical formula: (NH3)2.PtCl2 = 300.1.
CAS — 15663-27-1.
ATC — L01XA01.
ATC Vet — QL01XA01.
Pharmacopoeias. In Chin., Eur., Int., Jpn, and US.
Ph. Eur. 6.2
(Cisplatin). A yellow powder or yellow or orangeyellow crystals. Slightly soluble in water
; practically insoluble in alcohol
; sparingly soluble in dimethylformamide
. A 0.1% solution in sodium chloride
0.9% has a pH of 4.5 to 6.0 immediately after preparation. Store in airtight containers. Protect from light.
USP 31 (Cisplatin). Store in airtight containers. Protect from light.
Incompatibility. Cisplatin is rapidly degraded in the presence of bisulfite or metabisulfite, 1,2 and admixture with preparations containing these as preservatives may result in loss of activity. 2 Sodium bicarbonate may also increase the loss of cisplatin from solution, and in some cases may cause precipitation. 3 The stability of cisplatin when mixed with fluorouracil is reported to be limited, with 10% loss of cisplatin in 1.2 to 1.5 hours. 4 Mixtures with etoposide 5 in sodium chloride 0.9% injection formed a precipitate if mannitol and potassium chloride were present as additives, but not when the diluent was glucose 5% with sodium chloride 0.45%. Turbidity has been reported 6 within 4 hours of mixing 0.1% solutions of cisplatin and thiotepa in glucose 5%. Cisplatin exhibits variable incompatibility with paclitaxel, depending on the paclitaxel concentration and the temperature. 7 Cisplatin reacts with aluminium causing loss of potency and precipitate formation. Needles, syringes, catheters or giving sets that contain aluminium should not be used for preparing or giving cisplatin. 1. Hussain AA, et al. Reaction of cis-platinum with sodium bisulfite. J Pharm Sci 1980; 69: 364–5. 2. Garren KW, Repta AJ. Incompatibility of cisplatin and Reglan Injectable. Int J Pharmaceutics 1985; 24: 91–9. 3. Hincal AA, et al. Cis-platin stability in aqueous parenteral vehicles. J Parenter Drug 673 respectively. Other malignancies where cisplatin may be employed, as discussed in the introduction to this chapter, include non-Hodgkin’s lymphomas, tumours of brain, endometrium, oesophagus, stomach, and anus, head and neck, and thymus, neuroblastoma, and sarcoma of bone and soft tissue.